Interestingly, although FGF19 CNV could be detected by FISH and has been shown to correlate with response to the multi-kinase inhibitor sorafenib in HCC [134], current FGFR inhibitor trials either employ mRNA expression or protein overexpression via immunohistochemistry for FGF19 [32]. The gene discussed is FGF19; the disease is hepatocellular carcinoma.